Annexon (NASDAQ:ANNX – Get Free Report) released its quarterly earnings data on Monday. The company reported ($0.37) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.30) by ($0.07), Zacks reports.
Annexon Price Performance
NASDAQ ANNX opened at $1.75 on Wednesday. The firm has a market capitalization of $192.00 million, a P/E ratio of -1.67 and a beta of 1.24. Annexon has a 1-year low of $1.29 and a 1-year high of $7.85. The business’s 50-day simple moving average is $1.98 and its 200-day simple moving average is $3.78.
Analysts Set New Price Targets
Separately, Needham & Company LLC decreased their price target on Annexon from $16.00 to $11.00 and set a “buy” rating on the stock in a research note on Tuesday.
Annexon Company Profile
Annexon, Inc, a clinical-stage biopharmaceutical company, discovers and develops medicines for treating inflammatory-related diseases. Its lead candidate is ANX005, an investigational full-length monoclonal antibody, which is in Phase 3 clinical trial for the treatment of patients with guillain-barré syndrome; completed Phase II clinical trial for treating Huntington's disease; and in Phase II clinical trial for the treatment of amyotrophic lateral sclerosis.
Featured Stories
- Five stocks we like better than Annexon
- How to Short Nasdaq: An Easy-to-Follow Guide
- Joby Just Flew Two Aircraft at Once—Here’s Why It Matters
- Growth Stocks: What They Are, What They Are Not
- 4 Recent Earnings Winners Riding Fresh Momentum in May
- How to Calculate Inflation Rate
- Tesla: Get Ready To See It Trading Above $400 Again
Receive News & Ratings for Annexon Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Annexon and related companies with MarketBeat.com's FREE daily email newsletter.
